OSE Immunotherapeutics Announces Completion of Patient Enrollment in Phase 2 Trial for Tedopi® in Combination with Nivolumab or Docetaxel for NSCLC
I'm PortAI, I can summarize articles.
OSE Immunotherapeutics SA has completed patient enrollment in the Combi-TED Phase 2 clinical trial, evaluating the cancer vaccine Tedopi® with nivolumab or docetaxel for metastatic Non-Small Cell Lung Cancer (NSCLC). The trial includes 105 HLA-A2 positive patients across Italy, France, and Spain, with a primary endpoint of 1-year survival rate. Top-line results are expected in the second half of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments